The effects of metformin on gut microbiota and the immune system as research frontiers

Diabetologia

Volumn 60, Issue 9, 2017, Pages 1662-1667

  Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Diabetes; Metformin; Microbiome; Microbiota immunity cancer

Indexed keywords

BIGUANIDE DERIVATIVE; METFORMIN; PHENFORMIN;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG TARGETING; GASTROINTESTINAL TRACT; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; LUNG TUBERCULOSIS; MALIGNANT NEOPLASM; MELANOMA; MICROBIOME; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONCOLOGY; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TARGET ORGAN; TISSUE SPECIFICITY; MICROFLORA;

GASTROINTESTINAL MICROBIOME; HUMANS; METFORMIN; MICROBIOTA;

EID: 85026745250     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4352-x     Document Type: Review

References (53)

1. Bailey CJ (2017) Metformin: historical overview. Diabetologia. doi:10.1007/s00125-017-4318-z
2. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20:953–966
3. An H, He L (2016) Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol 228:R97–106
4. Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2:778–790
5. Pryor R, Cabreiro F (2015) Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J 471:307–322
6. Kalender A, Selvaraj A, Kim SY et al (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11:390–401
7. Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546
8. Bridges HR, Sirvio VA, Agip AN, Hirst J (2016) Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. BMC Biol 14:65
9. Bridges HR, Jones AJ, Pollak MN, Hirst J (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462:475–487
10. Jalling O, Olsen C (1984) The effects of metformin compared to the effects of phenformin on the lactate production and the metabolism of isolated parenchymal rat liver cell. Acta Pharmacol Toxicol 54:327–332
11. Andrzejewski S, Gravel SP, Pollak M, St-Pierre J (2014) Metformin directly acts on mitochondria to alter cellular bioenergetics. Can Metab 2:12
12. Howell JJ, Hellberg K, Turner M et al (2017) Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab 25:463–471
13. + and aspartate production and determines cancer cell sensitivity to metformin. Cell Metab 24:716–727
14. Liang X, Giacomini KM (2017) Transporters involved in metformin pharmacokinetics and treatment response. J Pharm Sci. doi:10.1016/j.xphs.2017.04.078
15. Wang PY, Li J, Walcott FL et al (2017) Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest 127:132–136
16. Brunkwall L, Orho-Melander M (2017) The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia 60:943–951
17. Zmora N, Bashiardes S, Levy M, Elinav E (2017) The role of the immune system in metabolic health and disease. Cell Metab 25:506–521
18. Komaroff AL (2017) The microbiome and risk for obesity and diabetes. JAMA 317:355–356
19. Forslund K, Hildebrand F, Nielsen T et al (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262–266
20. Wu H, Esteve E, Tremaroli V et al (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. doi:10.1038/nm.4345
21. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031
22. David LA, Maurice CF, Carmody RN et al (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:559–563
23. Karlsson FH, Tremaroli V, Nookaew I et al (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:99–103
24. Qin J, Li Y, Cai Z et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60
25. Cabreiro F, Au C, Leung KY et al (2013) Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153:228–239
26. Weinberg ED (1968) Antimicrobial activities of biguanides. Ann N Y Acad Sci 148:587–600
27. McCreight LJ, Bailey CJ, Pearson ER (2016) Metformin and the gastrointestinal tract. Diabetologia 59:426–435
28. Chandel NS, Avizonis D, Reczek CR et al (2016) Are metformin doses used in murine cancer models clinically relevant? Cell Metab 23:569–570
29. Buse JB, DeFronzo RA, Rosenstock J et al (2016) The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39:198–205
30. Pedersen HK, Gudmundsdottir V, Nielsen HB et al (2016) Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535:376–381
31. Perry RJ, Peng L, Barry NA et al (2016) Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature 534:213–217
32. Grasset E, Puel A, Charpentier J et al (2017) A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut–brain axis mechanism. Cell Metab 25:1075–1090.e1075
33. Duca FA, Cote CD, Rasmussen BA et al (2015) Metformin activates a duodenal AMPK-dependent pathway to lower hepatic glucose production in rats. Nat Med 21:506–511
34. Blagih J, Coulombe F, Vincent EE et al (2015) The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42:41–54
35. Pearce EL, Walsh MC, Cejas PJ et al (2009) Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460:103–107
36. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H (2015) Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 112:1809–1814
37. Kim SH, Li M, Trousil S et al (2017) Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma. J Invest Dermatol. doi:10.1016/j.jid.2017.03.033
38. Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM (2017) Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res 5:9–16
39. Cameron AR, Morrison VL, Levin D et al (2016) Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 119:652–665
40. Moiseeva O, Deschenes-Simard X, St-Germain E et al (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 12:489–498
41. Hirsch HA, Iliopoulos D, Struhl K (2013) Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 110:972–977
42. Cheng SC, Quintin J, Cramer RA et al (2014) mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345:1250684
43. Negrotto L, Farez MF, Correale J (2016) Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol 73:520–528
44. + T cell metabolism reverses lupus. Sci Transl Med 7:274ra218
45. san/san mice through inhibiting B cell differentiation into plasma cells via regulation of AMPK/mTOR/STAT3. J Immunol 198:2661–2670
46. Rajeshkumar NV, Yabuuchi S, Pai S et al (2017) Treatment of pancreatic cancer patient-derived xenograft panel with metabolic inhibitors reveals efficacy of phenformin. Clin Cancer Res doi:10.1158/1078-0432.CCR-17-1115/
47. Pollak M (2012) Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res 18:2723–2725
48. Kordes S, Pollak MN, Zwinderman AH et al (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16:839–847
49. Singhal A, Jie L, Kumar P et al (2014) Metformin as adjunct antituberculosis therapy. Sci Transl Med 6:263ra159
50. Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE (2014) Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care 37:2253–2260
51. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA (2016) Metformin as a tool to target aging. Cell Metab 23:1060–1065
52. Martin-Montalvo A, Mercken EM, Mitchell SJ et al (2013) Metformin improves healthspan and lifespan in mice. Nat Commun 4:2192
53. Klil-Drori AJ, Azoulay L, Pollak MN (2017) Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol 14:85–99